Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer ...

An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

The FDA approved Opdualag on the strength of the ... BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a monotherapy for melanoma since 2011 and as ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.

SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...

New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused ...